Member Info for RayPointer

"It also sounded to me like Lindy had an idea of their value to BioNtech and if they conclude they need to do a deal with us on moditope we will not be 'giving away' anything :)"

Agreed crumbs, a very smart move

What BionTech and Genentech bring to the GC is

a) An efficient TCR process
b) Diagnostics for individual patients

If I were CRUK I would give much more than 20 million to this project.
This could well turn out to be by far the most effective Cancer project so far.

It also may not be that long before it achieves results.

There are unknowns to the above statement

a) How much work has Lindy already done to identify the targets for these cancers?
b) Is BionTech's TCR technology ready to go
c) How far along are the diagnostics

I kind of like the idea of joint project managers, if that turns out to be true as reported on this BB

Lindy to manage developing Modi3
Ugur to manage the rest of the project (TCR and diagnostics)

IMHO

I just think it is possible (maybe probable) that they have done all this work and not actually found important targets.

If the project was going well:

1) Why join Lindy's GC team?
2) Why is Ugur collaborating with Scancell?
3) Whyh is Ugur intrigued by Moditope (Lindy's words at the calculus presentation)?

The 37 reasons for this are the moditope target!
All IMHO

C7

The following 2 paragraphs are taken from the atricle

"In 2012, a team of German researchers, led by scientists at BioNTech, sequenced a widely used mouse tumor cell line designed to mimic human melanoma cells. They identified 962 mutations and used RNA sequencing to identify 563 that were expressed in genes. The group then created vaccines made of protein fragments that contained 50 of the mutations and injected them into mice to see if this would prime the immune system to respond. About one third—16 of the mutations—were detected by the immune system, and five of those generated an immune response designed specifically to attack any cell found to harbor such mutations."

"At the urging of Mellman, Delamarre took Genentech’s own lab mice and sequenced their tumor cells, identifying 1,200 individual mutations not present in normal tissue. Then she measured how T cells naturally responded to them. Of those 1,200 mutations, she found, the mice’s immune system had begun to mount attacks against only two."

The above 2 paragraphs sound to me like a scatter-gun approach. Let's try every target we can think of and keep narrowing it down. I suspect you need a lot of money and resources to do this.

Contrast this to Lindy with little money and few resources and yet she comes up with effective vaccines (some still to be proved in the clinic). I just think her science is much better directed. She just has more knowledge IMHO.

I find it fascinating that Genentech and BionTech have worked for 6 years on personalised vaccines at great cost, and now find themselves as part of Lindy's GC team.

One thing is certain; Lindy does not have the same constraints as Ira Mellman; She does what she wants to do and also does it at minimal cost.

Perhaps she just just knows what avenues to pursue rather than adopting the apparant scatter-gun approach that Genentech and BionTech are pursuing.

that Moditope the vaccine is the main course and TCR treatment based on Moditope and diagnostics are the leftovers.
Cancer treatment is a huge market so the leftovers are very big, but maybe not nearly the size of the main course.

https://www.bbc.co.uk/news/blogs-trending-46317727

Let's hope another Basel organisation treat women better, especially a certain woman!

At this stage I think it is very much groundwork in making and developing Chinese contacts.
So, if and when the trials are successful (or just 1 trial as LD suggested) then we have the contacts in place to start negotiating.
We know Scancell already have NDAs in place, presumably with European and/or US companies. So adding Chinese companies to that list can only be beneficial when the real bargaining starts.
IMHO

Yes Rats
And have you noticed that Scancell's relationships never end in divorce?
The relationships with Nottingham Trent and Karolinski are also slow burners but still alight.

SCIB1 and SCIB2 are DNA based vaccines.

However, it is great to see a Scancell connection to CRUK at this early date.

I see Hygea and Oxford Technology have remained faithful holders certainly since 2008.

Ruck

I think the only person who can give a definitive answer on the similarities between the 2010 vaccine and SCIB1 now is Lindy herself.
With reference to Wild's post yesterday, by 2010 Lindy was well into the phase in her career where she was looking for fragments of much larger molecules as targets. Perhaps there is an overlap between the 2010 vaccine targets and SCIB1 targets.
Not important now as immunobody has patents granted.

The man appears to be corrupt but it doesn't mean he isn't a good scientist.

Anyway, there have been scientists since who have praised the SCIB1 trial in the peer report so it is hardly relevant now.

The man appears to be corrupt but it doesn't mean he isn't a good scientist.

Anyway, there have been scientists since who have praised the SCIB1 trial in the peer report so it is hardly relevant now.

Ruck

The clue is in the 1st para

"The long-awaited jab, described as a holy grail of cancer medicine, is to be tested on the first British patients within weeks. Research shows it can reverse and even cure melanoma, one of the deadliest forms of the disease, most commonly associated with skin cancer."

Hi Ruck

https://www.express.co.uk/news/uk/175410/Cancer-scientists-hail-huge-leap-towards-jab-that-targets-tumours

The express also reported it as an earlier version of SCIB1.

"The family of glowing young mother Amy Dickenson swear the treatment in an earlier form saved her life.
A version was tested on Amy when she was just eight and had advanced bone cancer in her leg."

Ruck

Found it. It was a post from Shri9 on iii.

https://www.ii.co.uk/discussion/t/why-scancell-is-unique/636181

Chelsea

Karol Sikora got into trouble with a cancer diagnosis on one of the Lockerbie bombers.

https://en.wikipedia.org/wiki/Karol_Sikora

Hi Ruck
I seem to remember reading somewhere that it was an early version of SCIB1.
I will have a look around to see if I can find it.

https://www.dailymail.co.uk/health/article-1278836/Holy-Grail-cancer-vaccine-blasts-tumours-weeks-hailed-huge-leap-fighting-disease.html

First 2 cures for an early version of SCIB1 were for bone cancer!

This has no doubt been previously posted but it is still a great story. I certainly remember this story and it was one of the reasons I invested in SCLP in the first place.

No mention of dual presentation of the vaccine to the APC.
This is the aspect of immunobody (Lindy believes this to be unique) that causes the activation of CD8 and CD4 cells in sufficient number to trigger clonal expansion.
I wonder how Lindy discovered this?